Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer ...

Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg ...

From biotechnology laboratories to regional workshops, from food innovation to digital platforms, women across North Queensland are building businesses designed to solve real-world problems at scale.

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outs ...

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outs ...

March 4, 2026) - Crossroads Gold Corp. (TSXV: CRG) (the "Company" or "Crossroads") is pleased to announce, further to the ...

The Mark Foundation for Cancer Research today announced four recipients of the 2026 Drug Discovery Awards, a program designed to bridge the gap between academic discovery and clinical application.

Strategic leadership changes -- Eran Ophir became CEO in September 2025, with Anat Cohen-Dayag transitioning to Executive Chair to enhance operational focus and strategic continuity.

Standard Uranium and Collective are pleased to announce plans for an inaugural drill program at the Project, located south of ...

Get each new episode of Bruce Whitfield’s weekly podcast delivered to your inbox to hear his take on business without the boring bits. Contact the public editor with feedback for our journalists, ...

VANCOUVER, British Columbia, Feb. 27, 2026 (GLOBE NEWSWIRE) — King Copper Discovery Corp. (“King Copper” or the “Company”) (TSXV: KCP) (OTCQB: TBXXF) (Frankfurt: 3RI0) is pleased to announce key ...

AbCellera Biologics Inc. (NASDAQ: ABCL) Q4 2025 Earnings Call Transcript February 24, 2026 AbCellera Biologics Inc. beats earnings expectations. Reported EPS is $-0.02995, expectations were $-0.18.